Quick Answer
Structure Therapeutics Inc. reported Cash and Equivalents of $799.62 million for fiscal year 2025.
Structure Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $799.62M | +371.7% |
| 2024 | $169.51M | +30.6% |
| 2023 | $129.79M | +397.5% |
| 2022 | $26.09M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $102.91M | -40.2% | -30.0% |
| June 30, 2025 | $147.02M | -61.5% | -3.4% |
| March 31, 2025 | $152.12M | +55.5% | -10.3% |
| December 31, 2024 | $169.51M | +30.6% | -1.5% |
| September 30, 2024 | $172.13M | +239.9% | -54.9% |
| June 30, 2024 | $381.63M | +840.2% | +290.1% |
| March 31, 2024 | $97.83M | -22.7% | -24.6% |
| December 31, 2023 | $129.79M | +397.5% | +156.3% |
- Structure Therapeutics Inc. showed an increase of +371.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, Structure Therapeutics Inc.’s cash and equivalents has grown by 2964.7% (from $26.09 million to $799.62 million).
- The most recent figure is from Structure Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: